A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

Rheumatology International

Volumn 30, Issue 11, 2010, Pages 1437-1440

  Giardina, Anna Rita ^a   Ferrante, Angelo ^a   Ciccia, Francesco ^a   Impastato, Rosalia ^a   Miceli, Maria Concetta ^a   Principato, Alfonso ^a   Triolo, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ankylosing spondylitis; Etanercept; Infliximab

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INFECTION; INJECTION SITE REACTION; MALE; OPEN STUDY; OPTIC NEURITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREATMENT OUTCOME; UVEITIS; VERTIGO;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955446605     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1157-3     Document Type: Article

References (19)

1. MA Khan 2002 Update on spondyloarthropathies Ann Intern Med 135 896 907
2. J Zochling D van der Heijde M Dougados, et al. 2006 Current evidence for the management of ankylosing spondylitis: systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Ann Rheum Dis 65 423 432 10.1136/ard.2005.041129 1:CAS:528:DC%2BD28XjslWjtLk%3D 16126792
3. M Rudwaleit T Hohler 2001 Cytokine gene polymorphisms relevant for the spondyloarthropathies Curr Opin Rheumatol 13 250 254 10.1097/00002281-200107000- 00002 1:CAS:528:DC%2BD3MXnt1SltrY%3D 11555724 (Pubitemid 32831814)
4. JC Davis DM van der Heijde J Braun, et al. 2008 Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis Ann Rheum Dis 67 346 352 10.1136/ard.2007.078139 1:CAS:528:DC%2BD1cXjs1ejs74%3D 17967833 (Pubitemid 351281269)
5. J Brandt A Khariouzov J Listing H Haibel, et al. 2003 Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis Rheum 48 1667 1675 10.1002/art.11017 1:CAS:528:DC%2BD3sXltlSgu70%3D 12794835 (Pubitemid 36682375)
6. JC Davis DM van der Heijde J Braun, et al. 2003 Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis Arthritis Rheum 48 3230 3236 10.1002/art.11325 1:CAS:528:DC%2BD3sXpvVygtb0%3D 14613288 (Pubitemid 37409337)
7. A Calin BAC Dijkmans P Emery, et al. 2004 Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis 63 1594 1600 10.1136/ard.2004.020875 1:CAS:528:DC%2BD2cXhtFaktbjM 15345498 (Pubitemid 39573687)
8. J Brandt J Listing H Haibel, et al. 2005 Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Rheumatology 44 342 348 10.1093/rheumatology/keh475 1:CAS:528:DC%2BD2MXhslSksrw%3D 15561737 (Pubitemid 40361291)
9. J Braun J Brandt J Listing, et al. 2002 Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 1187 1193 10.1016/S0140-6736(02)08215-6 1:CAS:528:DC%2BD38XivVShsro%3D 11955536 (Pubitemid 34304258)
10. J Braun J Brandt J Listing, et al. 2005 Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis Ann Rheum Dis 64 229 234 10.1136/ard.2004.025130 1:CAS:528:DC%2BD2MXhvFyrtbk%3D 15388511 (Pubitemid 40193618)
11. D van der Heijde B Dijkmans P Geusens, et al. 2005 Efficacy and safety of infliximab in patients with ankylosing spondylitis Arthritis Rheum 52 582 591 10.1002/art.20852 15692973 (Pubitemid 40216323)
12. H Marzo-Ortega D McGonagle S Jarrett, et al. 2005 Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study Ann Rheum Dis 64 1568 1575 10.1136/ard.2004.022582 1:CAS:528:DC%2BD2MXht1eksrjO 15829577 (Pubitemid 41532039)
13. J Braun J Brandt J Listing, et al. 2003 Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis Arthritis Rheum 48 2224 2233 10.1002/art.11104 1:CAS:528:DC%2BD3sXntVWgsbs%3D 12905476 (Pubitemid 36959203)
14. J Braun R Landewé KGA Hermann, et al. 2006 Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study Arthritis Rheum 54 1646 1652 10.1002/art.21790 1:CAS:528:DC%2BD28XlsFWjsrc%3D 16646033
15. MC Hochberg MG Lebwohl SE Plevy KF Hobbs DE Yocum 2005 The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin Arthritis Rheum 34 819 836 10.1016/j.semarthrit.2004.11.006 1:CAS:528:DC%2BD2MXks1Cqsbg%3D 15942917 (Pubitemid 40740207)
16. S Van der Linden HA Valkenburg A Cats 1984 Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria Arthritis Rheum 27 361 368 10.1002/art.1780270401 6231933
17. JJ Anderson G Baron D van der Heijde DT Felson M Dougados 2001 Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis Rheum 44 1876 1886 10.1002/1529-0131(200108) 44:8<1876::AID-ART326>3.0.CO;2-F 1:STN:280:DC%2BD3MvmtlGntw%3D%3D 11508441 (Pubitemid 32758236)
18. TR Jenkinson PA Mallorie HC Whitelock LG Kennedy SL Garrett A Calin 1994 Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index J Rheumatol 21 1694 1698 1:STN:280:DyaK2M%2Fpslaquw%3D%3D 7799351
19. JL Fernández-Sueiro A Willisch S Pértega-Díaz, et al. 2009 Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis Arthritis Rheum 61 3 386 392 10.1002/art.24280 19248134